Table 2.
Complete response rate according to compliance for treatment
| High CXI (n = 173) | Intermediate CXI (n = 36) | Low CXI (n = 57) | P | |
|---|---|---|---|---|
| CR in all patients | 145/173 (83.8) | 25/36 (69.4) | 27/57 (47.4) | <0.001 |
| CR in patients who completed treatment without DA | 85/92 (92.4) | 11/17 (64.7) | 9/12 (75.0) | 0.007 |
| CR in patients who completed treatment with DA | ||||
| DA, any degree | 56/63 (88.9) | 12/14 (85.7) | 15/21 (71.4) | 0.065 |
| DA ≥ 75% a | 41/47 (87.2) | 8/8 (100.0) | 13/17 (76.5) | 0.386 |
| DA < 75% b | 15/16 (93.8) | 4/6 (66.7) | 2/4 (50.0) | 0.031 |
| CR in patients who early discontinued treatment c | 4/18 (22.2) | 2/5 (40.0) | 3/24 (12.5) | 0.400 |
Abbreviations: CR, complete response; CXI, cachexia index; DA, dose adjustment.
a
Relative dose intensity of cyclophosphamide and doxorubicin ≥75%.
b
Relative dose intensity of cyclophosphamide and/or doxorubicin <75%.
c
Not due to disease progression.
Data are presented as number of patients (%).